TheraME! peer-reviewed, high impact
Publications

Combi-seq for multiplexed transcriptome-based profiling of drug combinations using deterministic barcoding in single-cell droplets. Nat Commun 13, 4450 (2022). Mathur, L., Szalai, B., Du, N.H. et al.
Technological and computational advances driving high-throughput oncology. Trends Cell Biol. 2022 Nov;32(11):947-961. Kolmar L, Autour A, Ma X, Vergier B, Eduati F, Merten CA.
A microfluidic Braille valve platform for on-demand production, combinatorial screening and sorting of chemically distinct droplets. Utharala, R., Grab, A., Vafaizadeh, V. et al. Nat Protoc (2022)
Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies. Eduati F, Jaaks P, Wappler J, Cramer T, Merten CA, Garnett MJ, Saez-Rodriguez J. Molecular Systems Biology (16)e8664: 1-13, 2020
Microfluidics as an Enabling Technology for Personalized Cancer Therapy. Mathur L*, Ballinger M*, Utharala R*, Merten CA. Small. E1904321: 1-18, 2019
A microfluidics platform for combinatorial drug screening on cancer biopsies. Eduati F*, Utharala R*, Madhavan D, Neumann UP, Longerich T, Cramer T, Saez-Rodriguez J, Merten CA. Nature Communications. 9(1):2434: 1-13, 2018